Monopar Therapeutics (MNPR) Financial Statements (2026 and earlier)

Company Profile

Business Address 1000 SKOKIE BLVD SUITE 350
WILMETTE, IL 60091
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

3/31/2026
MRQ
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:122,71045,8167,26612,18220,30416,737
Cash and cash equivalent61,83445,8167,2668,18620,30416,737
Short-term investments60,876     
Other undisclosed cash, cash equivalents, and short-term investments    3,996  
Other current assets6479664621863
Other undisclosed current assets17,69014,396 937  
Total current assets:140,46360,2917,33313,16620,52216,800
Noncurrent Assets
Operating lease, right-of-use asset255 1361  
Other noncurrent assets      69
Total noncurrent assets:255 1361 69
TOTAL ASSETS:140,71860,2917,34513,22720,52216,869
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:2,7352,2541,7573,1291,5811,177
Other undisclosed accounts payable and accrued liabilities2,7352,2541,7573,1291,5811,177
Total current liabilities:2,7352,2541,7573,1291,5811,177
Noncurrent Liabilities
Liabilities, other than long-term debt155  8  
Operating lease, liability155  8  
Total noncurrent liabilities:155  8  
Other undisclosed liabilities  3,000    
Total liabilities:2,8905,2541,7573,1371,5811,177
Equity
Equity, attributable to parent137,82855,0375,58810,09018,94115,692
Common stock7615131311
Additional paid in capital227,199130,78765,79361,87260,22047,874
Accumulated other comprehensive income (loss)13136(14)9(3)(8)
Accumulated deficit(89,510)(75,793)(60,206)(51,804)(41,288)(32,185)
Total equity:137,82855,0375,58810,09018,94115,692
TOTAL LIABILITIES AND EQUITY:140,71860,2917,34513,22720,52216,869

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenues
(Other Income)		      122
Cost of revenue
(Cost of Product and Service Sold)		    (83)  
Gross profit:    (83) 122
Operating expenses(16,704)(16,162)(8,831)(10,537)(9,127)(6,509)
Other undisclosed operating income (loss)    83 (122)
Operating loss:(16,704)(16,162)(8,831)(10,537)(9,127)(6,509)
Nonoperating income2,988575    
Investment income, nonoperating2,988404    
Other nonoperating income  171    
Loss from continuing operations before equity method investments, income taxes:(13,717)(15,586)(8,831)(10,537)(9,127)(6,509)
Other undisclosed income from continuing operations before income taxes11    
Loss from continuing operations before income taxes:(13,716)(15,586)(8,831)(10,537)(9,127)(6,509)
Income tax expense (1)(1)    
Other undisclosed loss from continuing operations      
Loss from continuing operations:(13,717)(15,586)(8,831)(10,537)(9,127)(6,509)
Loss before gain (loss) on sale of properties:✕✕✕✕✕(9,127)(6,509)
Other undisclosed net income    21  
Net loss:(13,717)(15,586)(8,831)(10,516)(9,127)(6,509)
Other undisclosed net income attributable to parent 0 429 24204
Net loss available to common stockholders, diluted:(13,717)(15,586)(8,402)(10,516)(9,103)(6,305)

Comprehensive Income ($ in thousands)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Net loss:(13,717)(15,586)(8,831)(10,516)(9,127)(6,509)
Other comprehensive income    1253
Comprehensive loss:(13,717)(15,586)(8,831)(10,504)(9,123)(6,506)
Other undisclosed comprehensive income, net of tax, attributable to parent9550406 24204
Comprehensive loss, net of tax, attributable to parent:(13,621)(15,536)(8,425)(10,504)(9,099)(6,301)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: